Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 39Breast Neoplasms 24Neoplasms 12Prostatic Neoplasms 11Triple Negative Breast Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Fanconi Anemia, Complementation Group D1 5Small Cell Lung Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Solid Tumors 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Colorectal Neoplasms 2Carcinoma 2Advanced Solid Tumours 2Advanced Solid Tumor 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Metastatic Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Platinum-sensitive Ovarian Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1

Interventions

Gemcitabine 22Fluorouracil 14Oxaliplatin 13Capecitabine 13Paclitaxel 12pembrolizumab 11Cisplatin 11Carboplatin 11Pemetrexed 10Leucovorin 9130-nm albumin-bound paclitaxel 9Ramucirumab 8zolbetuximab 7Albumin-Bound Paclitaxel 7trastuzumab deruxtecan 6Drug Therapy 5Docetaxel 5Bevacizumab 5Nivolumab 4Irinotecan 4vandetanib 3cemiplimab 3Everolimus 3EC145 3tislelizumab 2technetium 99m etarfolatide 2spartalizumab 2pralsetinib 2osimertinib 2nimotuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma × olaparib × Clear all
NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Opna Bio LLC

Phase 1/2 Terminated
19 enrolled 11 charts
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡